Nottingham, United Kingdom

James Carmichael

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 18.9

ph-index = 2

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of James Carmichael

Introduction

James Carmichael is a notable inventor based in Nottingham, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antiproliferative compounds. With a total of three patents to his name, Carmichael's work is focused on advancing treatments for serious medical conditions.

Latest Patents

Carmichael's latest patents include innovative compounds designed for the treatment, prevention, or management of multiple myeloma. One of his key inventions is a compound described as 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile. This compound, along with its enantiomers, mixtures, tautomers, and pharmaceutically acceptable salts, represents a significant advancement in cancer treatment. The patent also details pharmaceutical compositions that incorporate these compounds and methods for their use.

Career Highlights

Carmichael is currently employed at Celgene Corporation, where he continues to innovate in the pharmaceutical industry. His work has been instrumental in developing new therapies that aim to improve patient outcomes in oncology.

Collaborations

Carmichael collaborates with esteemed colleagues, including Matthew David Alexander and Gerald D Artman, III. These partnerships enhance the research and development process, fostering an environment of innovation and discovery.

Conclusion

James Carmichael's contributions to the field of pharmaceuticals, particularly through his patented inventions, highlight his role as a key innovator in the fight against multiple myeloma. His work not only advances medical science but also offers hope for improved treatments for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…